References
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365:2205–2219.
- Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A. Pathogenesis of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp (AITE). 2011; 59:89–95.
- Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012; 91:30–43.
- Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011; 33:679–707.
- Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5:1731–1740.
- Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky V, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371:987–999.
- Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19:12–19.
- Emery P, Keystone E, Tony H, Cantagrel A, Vollenhoven R, Sanches A, et al. L-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-control led trial [RADIATE study]. Ann Rheum Dis. 2008; 67:1516–1523.
- Felson DT, Smolen JS, Wells G, Zhang B, Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthr Rheum. 2011; 63:573
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988; 31:315–324.
- DAS-score NL. Home of the DAS. http://www.das-score.nl/.
- Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score(DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007; 66:407–409.
- Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis. 2011; 70:1999–2002.
- Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006; 18:277–281.
- Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2011 Epub ahead of print.
- Vermeer M, Kuper HH, Bijl AE, Baan H, Posthumus MD, Brus HL, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012; 50:1908–1915.
- Dougados M, Ripert M, Hilliquin P, Fardellone P, Brocq O, Brault Y, et al. The influence of the definition of patient global assessment in assessment of Disease Activity According to the Disease Activity Score (DAS28) in rheumatoid arthritis. J Rheumatol. 2011; 38:2326–2328.